Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 04/04/24
Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 02/28/24
Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 02/28/24
Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024GlobeNewsWire • 02/21/24
Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/20/24
Mersana Therapeutics to Participate in Guggenheim's 6th Annual Biotechnology ConferenceGlobeNewsWire • 02/01/24
Mersana Therapeutics Announces Business Updates, Expected 2024 Milestones and Upcoming Presentation at the 42nd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/05/24
Mersana Therapeutics Provides Business Update and Announces Third Quarter 2023 Financial ResultsGlobeNewsWire • 11/07/23
Mersana Therapeutics to Host Third Quarter 2023 Conference Call on November 7, 2023GlobeNewsWire • 10/31/23
Mersana Therapeutics Announces FDA has Lifted Clinical Hold on Phase 1 Clinical Trial of XMT-2056GlobeNewsWire • 10/31/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mersana Therapeutics, Inc. - MRSNPRNewsWire • 08/18/23
After Plunging -68.18% in 4 Weeks, Here's Why the Trend Might Reverse for Mersana Therapeutics, Inc. (MRSN)Zacks Investment Research • 08/18/23
Down -64.71% in 4 Weeks, Here's Why Mersana Therapeutics, Inc. (MRSN) Looks Ripe for a TurnaroundZacks Investment Research • 08/16/23
Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research • 08/08/23
Mersana Therapeutics Announces Topline Data from UPLIFT Clinical Trial in Patients with Platinum-Resistant Ovarian Cancer and Strategic ReprioritizationGlobeNewsWire • 07/27/23
MRSN FRAUD ALERT: Jakubowitz Law is Investigating Mersana Therapeutics, Inc. in Connection with Potential Violations of Federal Securities LawsPRNewsWire • 06/27/23
MRSN NEWS: The Klein Law Firm Initiates an Investigation Involving Possible Securities Fraud Violations by Officers of Mersana Therapeutics, Inc.PRNewsWire • 06/27/23
MRSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities LawsPRNewsWire • 06/26/23
MSN ALERT: The Law Offices of Vincent Wong Investigate Mersana Therapeutics, Inc. for Potential Violations of Securities LawsPRNewsWire • 06/22/23